doi:10.1161/JAHA.119.015716 46
Clinical Highlights of Retatrutide Study: 48-week, double-blind, placebo-controlled Phase 2 trial Results: ~22.8% weight loss (8 mg dose), ~28.2% weight loss (12 mg dose) ~0.9% HbA1c reduction Significant improvements in cardiometabolic risk factors Safety & Tolerability Most common side effects: nausea, vomiting, diarrhea, abdominal discomfort, constipation typically mild to moderate and dose-dependent
However, without specific studies on intramuscular semaglutide administration, these effects remain uncertain
Recurrence of symptoms occurred in only one case involving a deviation from the guidelines
50 This age discrepancy is thought to be due to the gradual weakening of the immune system with age, a process called immune senescence
Compounded Semaglutide and Compounded Tirzepatide are also available through certain programs